We expect 2027 to be remembered as the year that HealthTech investors and founders stopped treating hardware as the difficult, capital hungry cousin of software and started treating it as the foundation of a defensible business. The moat, it turns out, was never the code. It was the thing the code runs on.

The consumer digital health sector is undergoing a structural transition from episodic, reactive vital sign tracking toward continuous, multimodal physiological synthesis and proactive longevity modeling. The hardware introduction of the Apple Watch Series 12 and Apple Watch Ultra 4, coupled with the architectural overhaul of the Apple Health application under iOS 27, marks a significant convergence of high-frequency wearable photoplethysmography, on-device computer vision, g

For most of medical history, if you wanted to know what was happening inside a person's body, you had to break the skin. Blood is the gold standard for almost every biomarker clinicians care about, and getting at it means needles, vials, laboratories and waiting. Even the most celebrated success in wearable biosensing, the continuous glucose monitor, still relies on a filament pushed under the skin to sample interstitial fluid. Sweat has always been the obvious alternative. I

For most of the last three years, the story of metabolic health has been told as a pharmaceutical story. Semaglutide and tirzepatide rewrote the economics of obesity, turned Novo Nordisk and Eli Lilly into two of the most valuable companies in the world, and pulled a once-marginal clinical category into the centre of health policy. In the first nine months of 2025 alone, Lilly's Mounjaro and Zepbound generated $39.5 billion in revenue, overtaking Keytruda as the world's best-

The relationship between medical technology and defence technology is not a one-way transfer from one sector to the other. It is a symbiosis. Defence sets the hardest constraints imaginable and funds the work to overcome them; medicine supplies the clinical knowledge, the regulatory pathways and the vast civilian market that turns a prototype into a product. Each side changes the other. And as artificial intelligence, autonomy and miniaturisation converge, the two are moving

The Phoenix Partnership (Leeds) Ltd (TPP) represents one of the most profitable and entrenched software platforms within the United Kingdom's digital health infrastructure. Operating its proprietary electronic health record (EHR) platform, SystmOne, TPP maintains an entrenched duopoly alongside EMIS Health, together administering the clinical data and consultation workflows of more than 90% of general practices across England. In the financial year ending 31st March 2025, TPP

The European healthcare technology landscape has transitioned from the speculative, top line driven environment of the Zero Interest Rate Policy (ZIRP) era into an industrial phase centred on capital efficiency, clinical efficacy and regulatory defensibility. Valued at $96.68 billion in 2025, the European HealthTech sector is projected to reach $222.22 billion by 2030, representing a compound annual growth rate (CAGR) of 18.11%. Concurrently, the European MedTech sector repre

The acquisition of Icario by Vitality Group International, a wholly owned subsidiary of the South African financial services group Discovery Limited, represents an important structural consolidation within the healthcare member engagement and behavioural change sector. Formally executed on September 1st, 2026, and publicly announced on September 3rd, 2026, the transaction establishes an integrated health engagement enterprise serving approximately 19

The integration of ambient artificial intelligence (AI) scribes into healthcare delivery represents one of the most rapid technological adoptions in modern clinical informatics. Powered by automatic speech recognition (ASR), natural language processing (NLP) and large language models (LLMs), these systems passively capture multi-party acoustic dialogue within the clinical encounter and synthesise unstructured clinical discourse into structured documentation. Health system lea

Nelson Advisors LLP is a London headquartered investment banking and corporate finance advisory boutique established in 2023 that operates exclusively within the European Healthcare Technology (HealthTech), Medical Technology (MedTech), and Healthcare Artificial Intelligence (Healthcare AI) sectors. Headquartered at Hale House, 76–78 Portland Place in Marylebone, London, the firm advises clients within the lower to middle market, concentrating on transactions with enterprise

The wearable technology landscape is reaching an inflection point, transitioning from passive biometric data loggers to active, edge-native ambient computing platforms. Bengaluru-based health technology firm Ultrahuman has positioned itself at the center of this architectural pivot by securing a $70 million financing round backed by Qualcomm Ventures. This transaction reflects an aggressive operational attempt to expand the smart ring form factor beyond sleep, strain and

The European healthcare technology, medical devices (Medtech) and artificial intelligence (Health AI) ecosystems have transitioned from post-pandemic venture fragmentation into a disciplined era of industrial maturity. Following a severe liquidity drought that curtailed capital deployment and delayed public listings between late 2021 and 2024, the public offering window is reopening under fundamentally altered underwriting standards. Institutional public equity allocators no

The global soft-tissue robotic-assisted surgery (RAS) market is undergoing structural realignment, characterised by accelerating clinical adoption, broadening procedural indications, and an intensifying multi-platform challenge to incumbent monopolies. On September 1st, 2026, Medtronic plc announced an approximately $700 million strategic investment in Cornerstone Robotics, a Hong Kong-headquartered surgical robotics innovator. Concurrently, Medtronic secured exclusive commer

The Australian Digital Health Agency (ADHA) has finalised an open market procurement awarding Accenture Australia Pty Ltd a $161.6 million contract to deliver Application Support and Maintenance (ASM) services for the national My Health Record (MHR) infrastructure and associated API gateway. This procurement decision follows scrutiny from the Australian National Audit Office (ANAO), which published a performance audit detailing historical governance failures, uncompeted contr

The structural architecture of private capital deployment within lower middle market (LMM) healthcare and healthcare technology is undergoing a fundamental transformation. Historically, single family and multi family offices participated in middle market private equity primarily as passive Limited Partners (LPs), committing capital to traditional blind pool buyout funds or selectively participating in co-investments managed by institutional general partners (GPs).